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Current concepts in nanostructured contrast
media development for in vivo photoacoustic
imaging
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Photoacoustic (PA) imaging is indeed one of the most promising bioimaging techniques for theranostics
applications in humans, allowing for the visualization of blood vessels and melanomas with high spatial
resolution. However, in order to overcome the endogenous contrast arising from interfering endogenous
species such as haemoglobin and melanin, specific contrast agents need to be developed, allowing PAI to
successfully identify targeted contrast in the range of wavelengths in which interference from the bio-
matrix is minimized. This has been first performed by small molecule dyes, which, however, suffer from
some important limitations such as low hydrophilicity and short circulation times. For this reason, scien-
tific research has recently directed its efforts towards the development of nanostructured contrast agents
capable of providing efficient PA contrast at low concentrations with low toxicity and high biocompatibil-
ity. The principal nanostructures are based on (1) metal and semiconducting nanoparticles, amongst
which variously shaped nano-gold plays the main role, (2) carbon nanomaterials, such as carbon nano-
tubes and graphene, and (3) conjugated polymer nanoparticles. In this review, the principal characteristics
of this class of materials are reported and greater focus is directed towards in vivo studies. A detailed ana-
lysis is performed on various physical–chemical parameters that define the PA response of reported con-
trast agents, like absorption coefficients and photoacoustic efficiencies. By comparing the experimental
data, this review provides a comprehensive tool for the evaluation of new nanostructured contrast agents
for PA imaging.
Introduction
Photoacoustic (PA) imaging is an emerging technique based
on the illumination of a specimen with NIR nanosecond-
pulsed laser light and the absorption of photons by chromo-
phores in the sample results in the generation of acoustic
waves, which are then detected and processed to form an
image. Thanks to acoustic detection, it is often possible to
couple PA imaging to ultrasound (US) echographic systems:
ultrasounds are directed to the sample together with the laser,
scattered and diffused in the tissues and detected back by a
separate US detector.1 Although PA and US image formation
and the factors that affect spatial resolution are mostly the
same, the contrasts that generate the images are essentially
different. A US image describes the acoustic impedance mis-
match between different tissues: US contrast, therefore,
depends on the morphological features of the tissues, while
PA represents the initial pressure distribution produced by the
absorption of a pulse of laser light. The capability to perform
photoacoustic detection on non-transparent samples provides
the possibility of exploiting it for spectral characterization of
biologic tissues, for which traditional optical spectroscopic
tools cannot be generally applied. The field of optoacoustics
has rapidly grown in terms of development of instrumentation,
image processing algorithms, in vivo application of the tech-
nique in clinical medicine and basic biological research.2 In
photoacoustic (PA) imaging, ultrasound waves are generated by
irradiating tissues with modulated or pulsed laser light. For
applications in biology and biomedicine, optical wavelengths
in the near-infrared (NIR, 700–1500 nm) are applied due to the
high transparency of tissues in this range, achieving pene-
tration depths up to several centimeters. In this region of the
electromagnetic spectrum are located the two so-called biologi-
cal windows, in which the absorption from biological tissues
is minimized (or transparency is maximized). Recently, PA
imaging has emerged in biomedicine thanks to its easy trans-
lation in human studies and its remarkable features compared
to most other imaging techniques. PA imaging allows for extre-
mely high spatial resolution which is only limited by the tech-
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nological implementation of the ultrasonic transducer. With
respect to traditional optical imaging (fluorescence or phos-
phorescence), PA imaging employs a much longer irradiation
wavelength, with a consequent increase in penetration depth
and in safety associated with laser employment. Moreover, the
merging of light- and sound-based approaches allows for the
evaluation of molecular spectral features of the analysed speci-
men together with its morphological details, to which ultra-
sounds are mostly sensitive. Although organic tissues can
generate strong PA signals, the employment of specific con-
trast agents is desirable to retrieve detailed information, and
most of the research activity has focused on this aspect.
Within the field of photoacoustics, the currently most excit-
ing challenges are represented by the design and development
of nanostructured contrast agents associated with increasingly
higher contrast-to-noise ratios, little or no toxicity, and rapid
clearance from the circulatory vessels. In addition, by moving
the absorption of contrast agents to higher wavelengths, it will
be possible to achieve much greater penetration depths and
lower interference from endogenous chromophores. With this
approach, PA is predicted to become an extensively versatile
tool for diagnostics in medicine. With the present work, we
aim to review the fundamental applications of nanostructured
contrast agents for PA imaging of biological systems in vivo,
with a particular focus on the peculiar properties that allow
each of the different nanostructures to generate PA signals.
First, the main physical–chemical properties of nanostructures
will be examined, and then their PA performances will be com-
pared and the most remarkable results shown.
Endogenous contrast
Standard implementations for PA imaging require laser-emit-
ting light in the near-infrared window of the electromagnetic
spectrum (λ = 800–2000 nm) since shorter wavelengths would
be scattered and absorbed to a greater extent. Since NIR light
can achieve high penetration depth in biological tissues of the
order of several centimeters, part of the incoming photons will
be absorbed by chromophores naturally present in the tissues
such as lipids, water, collage, melanin and hemoglobin in its
two forms, oxygenated (Hb) and deoxygenated (HbO2); these
are referred to as endogenous chromophores (Fig. 1a).
Hemoglobin is an iron-based metalloprotein responsible for
the delivery of molecular oxygen throughout the body: it
undergoes structural and electronic modifications upon O2
binding, which results in a modification of its absorption spec-
trum. This allows measuring the total hemoglobin concen-
tration and oxygen saturation by multispectral PA imaging,
which provides helpful information for the study of tumor
angiogenesis.5–9 It is also worth mentioning the absorption be-
havior of lipids at long wavelengths (930 and 1210 nm) related
to the second overtone of the C–H stretching, which are abun-
dant in fatty acid chains.10,11 Contrast can arise from water if
excited at 975 nm, whereas melanin, thanks to its intense
absorption throughout the biological window, allows for the
detection and characterization of primary melanoma and
metastatic melanoma cells by PA imaging.12 However, melanin
strongly influences the penetration depth achievable with PA
imaging, drastically limiting the performances of PA imaging
in melanin-rich tissues. However, this can be exploited to
employ melanin-based nanomaterials as exogenous contrast
agents, after the required chemical modification.13 Anyway,
intrinsic chromophores only give access to a limited number
of applications in biological processes. In PA imaging for bio-
medical applications, these absorptions represent the back-
ground that must be overcome by efficient contrast agent
engineering capable of highlighting specific features of the
investigated biological system. The absorption profiles of
endogenous chromophores generate two distinct biological
windows in the NIR between 650 and 950 nm and the second
between 1000 and 1350 nm, separated by the strong absorp-
tion from lipids at 950–1000 nm (Fig. 1b). Even though
endogenous contrast can be significantly relevant for particu-
Fig. 1 Endogenous chromophores. (a) Absorption spectra of the main endogenous chromophores. At long wavelengths, the contribution of oxy-
and deoxy-hemoglobin is negligible but the interference of water and fat is increasing. Melanin covers the whole spectral range, strongly reducing
the optical penetration depth in melanin-rich regions. (b) Attenuation coefficients for oxygenated and deoxygenated blood, fat and skin, with the
two biological windows highlighted. Adapted from ref. 3 and 4.
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lar tissues or for particular excitation wavelengths, several
multivariate analysis tools have been developed for the resolu-
tion of the spectral mixtures in PAI. For example, the
implementation of multivariate curve resolution (MCR) algor-
ithms for the decomposition of multispectral PA images in dis-
tribution maps of the single components of the endogenous
PA contrast has been recently reported.14,15 The multivariate
separation of endogenous and exogenous contrast in PA
imaging is yet to be explored, but this could make contrast-
based PA imaging an important non-invasive diagnostic tool
in the near future.
Contrast media for PA imaging in vivo
In 2017 the global contrast agent market size was valued at
USD 4.89 billion and is anticipated to constantly grow (Fig. 2).
Leading categories in the market are barium-based, iodinated,
gadolinium-based, and microbubble contrast media: this is
attributable to the preferential exploitation in the clinical
approach of X-ray and CT procedures, as well as MRI pro-
cedures. However, these materials are currently under regulat-
ory scrutiny, which is expected to prove detrimental for the
market until the arrival of safer alternative agents. From
the application point of view, neurological disorders
account for the largest share, followed by cardiovascular dis-
orders and cancer. High applicability of imaging modalities
and accessibility to launched products for diagnosis of cancer
or other diseases are strongly required from the actual
market.16
As has already been discussed, the need for exogenous con-
trasts arises from the diffusion and non-specificity of endogen-
ous PA-responding macromolecules. Although endogenous
chromophores can provide useful information about blood
flow, oxygen saturation and lipid content, they do not make PA
suitable for the detection of specific diseases in vivo.
Contrariwise, smartly-engineered nanostructured contrast
media can be precisely designed for each particular appli-
cation in diagnostics and, sometimes, as theranostic agents.
In the present section, the most outstanding classes of exogen-
ous contrast media for PA imaging will be presented together
with their main physical–chemical properties. Firstly, mole-
cular contrast performed by small molecule dyes will be briefly
discussed, and then our focus will be mainly directed towards
nanostructured contrast agents which are currently available
in the literature.
Small molecule dyes
Small molecule dyes (SMDs) are polyconjugated organic
chromophores; for application as PA contrast agents in deep
tissues, absorption in the NIR is required. The optimal dye
shows extended conjugation, which leads to the contraction of
the HOMO–LUMO gap energies to energies corresponding to
the near-infrared region of the electromagnetic spectrum:
upon the absorption of NIR radiation, an electron of the dye is
promoted from its HOMO to its LUMO, and relaxation of the
excited states occurs via non-radiative processes (heat-wave),
leading to anisotropic photoacoustic emission. Moreover, the
fluorescence quantum yield of the dye should be as low as
possible to maximize photoacoustic efficiency and con-
trast.17,18 The brightest future for this class of PA contrast
media is expected to be experienced by the FDA-approved indo-
cyanine green (ICG) (Fig. 3a). It has a strong and characteristic
concentration-dependent absorption band at around 800 nm
in diluted solutions (Fig. 3d); it is water soluble and biocompa-
tible and shows intense fluorescence emission in the NIR
(around 850 nm) with low radiative quantum yield (2.7%).19,20
Its improved photoacoustic performances have been attributed
to the high lipophilicity of the molecule, which causes attrac-
tion between molecules by van der Waals interactions leading
to extensive non-radiative relaxation of the excited states gener-
ated by laser light absorption.21 The potential application as
PA contrast agents of ICG, existing in the free molecular form
or conjugated to specific targeting agents, has been widely
investigated in recent years, showing high plasma protein
binding and promising results as blood flow monitoring
agents and providing good tumor contrast.22–26 However, ICG
suffers from some important drawbacks shared with most
SMDs: poor aqueous stability, concentration-induced aggrega-
tion and quick clearance (around 2–4 min) from the body. In
parallel, other classes of dyes have been explored as contrast
Fig. 2 Left: market size trends expected for contrast agents. Right: application of contrast agents in 2017. Adapted from ref. 16.
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agents for molecular PA imaging; amongst these, methylene
blue (MB) has rapidly emerged thanks to its well-known bio-
compatibility and low photobleaching, together with its
unique optical properties due to its strong absorption band
centered at 664 nm (Fig. 3e), which may blue-shift with
increasing concentration due to oligomerization equilibria.27
The features of MB (Fig. 3b) have been recently exploited for
several in vivo studies displaying good photoacoustic contrast
in vivo after subcutaneous injection in mice for sentinel lymph
node detection and photoacoustic imaging of the bladder, but
due to the relatively shorter wavelength of the absorbed radi-
ation, poor penetration depth can be achieved.28–30
Another representative class of SMD are squaraine dyes,
characterized by an electron-deficient cyclobutene ring conju-
gated with two electron deficient groups (Fig. 3c); their optical
properties can be tuned to the NIR region by adjusting the
electron-donating strength of the conjugated groups.31 Even
though they show bright photoacoustic contrast due to their
longer absorption wavelength and lower fluorescence quantum
yield, their applications are limited by their intrinsic lipophili-
city and chemical reactivity.
Since the most important requirement for an organic dye to
be employed in PA is the NIR absorption, several different
classes of small molecule dyes have been developed and studied
in addition to the abovementioned compounds. Recently, appo-
sitely formulated naphthalocyanine dyes have been exploited as
PA signaling compounds, aiming to image in the NIR with
increasing sensitivity.32,33 In addition, other dyes such as
Prussian blue, Coomassie blue, BODIPYs (4,4-difluoro-4-bora-
3a,4a-diaza-s-indacenes), porphyrines and cyanines have been
explored for the purpose, showing good contrasts and sensing
behaviour in vivo.34,35,36–43,44 However, the development of new
small molecule dyes as contrast agents for preclinical PA
imaging is strongly limited by their molecular properties: the
high conjugation degree required for NIR absorption drastically
decreases the water-dispersibility properties of the dyes, leading
to low stability in aqueous media and concentration-dependent
optical properties. Moreover, no SMD capable of interacting
with light waves longer than 800 nm has been reported, and
their optical absorption coefficient is still quite low (<5000
M−1 cm−1) compared to most nanostructured photoabsorbers.
For these reasons, several methods have been developed
recently for coupling ICG, MB and other dyes to a different set
of nanostructures, like the encapsulation of dyes in bio-
degradable polymeric matrices such as PLA, PLGA and PLC,
which can drastically increase their circulation lifetimes and
their dispersibility in aqueous environments.45,46
While the encapsulation of dyes into polymeric micelles or
liposomes has ensured the overcoming of some of their draw-
backs, their coupling to metallic nanostructures (magnetic or
semiconducting) has allowed for increased stability and
imaging in multiple modalities.47–49 The formulation of dye-
conjugated nanosystems also allows for chemical functionali-
zation with specific targeting moieties leading to increased
specific local contrast.50–57
PA-responsive nanostructures
Photoacoustic-responsive nanostructures are composite nano-
materials capable of efficiently interacting with tissue-penetrat-
ing pulsed near-infrared light and to transform it into high-fre-
quency ultrasound waves that can be detected by piezoelectric
transducers to generate PA images. Their characteristics must
include: (1) small size (<200 nm), allowing for good dispersion
and active and passive tumor targeting;58,59 (2) good biocom-
patibility and minimum cytotoxicity;60 (3) high molar absorp-
tion coefficient in the NIR; (4) high photoacoustic efficiency
and low fluorescence quantum yield; (5) low photobleach-
ing.61,62 In addition, by smart coupling of the photoactive core
with other agents with specific activities, such as radiolabelled
compounds, paramagnetic structures or fluorescence probes,
multiple-modality imaging (PA-PET, PA-MRI, etc.) is allowed.63
The main classes of nanostructures used as contrast agents for
PA imaging are:
• Metal and semiconducting nanoparticles, whose optical
properties are due to their metallic core (surface plasmon reso-
nance or exciton absorption);
Fig. 3 Chemical structures of (a) ICG, (b) MB and (c) squaraine dyes, and UV-VIS spectra of (d) ICG at different concentrations and (e) MB.
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• Carbon nanomaterials, in which peculiar properties of
nanostructured carbon allotropes are exploited to generate
photoacoustic waves;
• Polymeric nanoparticles, composed of polyconjugated
polymers or polymers containing photoactive groups such as
porphyrin derivatives (HOMO–LUMO absorption).
Metal and semiconducting nanoparticles
In the field of nanomedicine, the role of transition metal
nanoparticles (MNPs) has rapidly grown due to the character-
istic properties that their compounds show at the nanoscale.64
The optical properties of MNPs can arise from localized
surface plasmon resonance (LSPR) in noble metal nano-
particles or from the formation of an exciton, an electron–hole
pair, in semiconducting nanostructures. Also, their surface
chemistry is relatively easy and well-known; therefore, it could
be exploited for chemical functionalization with biocompatibi-
lizing or targeting agents that need to be specifically developed
for each application. The optical properties of MNPs mostly
depend on their size and shape; thus, fine-tuning the para-
meters that determine the evolution of the morphology of the
nanoparticle in the synthesis steps is a key factor for the
obtainment of the desired properties in the final nanocon-
structs. For this reason, MNPs show finely tunable absorption
behavior in the NIR region of the electromagnetic spectrum,
and experimental evidence reports much higher molar extinc-
tion coefficients compared to NIR dyes. Finally, their high
thermal conductivity allows for improved conversion of the
energy of the absorbed radiation into thermal waves.
Gold. In the last two decades, researchers have focused on
the development of gold nanostructures due to their unique
optical and physicochemical properties, their relative inertness
and their prior use in humans. The optical properties of gold
nanoconstructs arise from the LSPR phenomenon generated
by the confinement of surface plasmons (coherent electron
oscillations) in nanosized noble metal systems when they are
hit by photons of light whose wavelengths are of the order of
magnitude of the nanoparticle size. This leads to the absorp-
tion of the photon, whose energy is efficiently converted into a
heat wave detectable by photoacoustic imaging. The energy
corresponding to the LSPR phenomenon is directly connected
to the maximum absorption wavelength of the particle, which
is a function of several physical–chemical features including
surface-to-volume ratio, polarization modes, shape and
size.65,66 By investigating the parameters that determine the
position of the LSPR band, it is possible to tune the absorption
maximum far from the visible to the NIR, making gold a very
promising tool for generating photoacoustic signals by exci-
tation in the NIR.67 In addition, elemental gold can form very
strong and almost-covalent bonds with thiol groups, with
bond energies of the order of around 250–300 kJ mol−1,
enabling surface functionalization with polymers or small
molecules bearing a thiol group.68 Thiolated ligands can
stabilize the high-energy surface of the nanoparticles by the
formation of well-ordered self-assembled monolayers (SAMs)
that can drastically increase the water stability properties of
gold nanostructures and allow for the introduction of func-
tional moieties for bioconjugation.69 Even though gold is gen-
erally referred to as non-toxic, the pharmacokinetics of gold
nanosystems is strongly dependent on their shape, size and
surface functionalization, and a general evaluation of the toxi-
cology of nano-gold cannot be made. Therefore, biocompatibil-
ity studies should be independently conducted in vivo or
in vitro for each nanoconstruct that is developed for appli-
cations in nanomedicine.70 Spherical gold nanoparticles
(AuNPs) can hardly find applications in imaging due to their
absorption behavior limited to the visible region of the electro-
magnetic spectrum, where tissue penetration is drastically
limited by absorption and scattering from the skin layer
(Fig. 4a). The surface plasmon peak red-shifts upon the
increase of particle size: controlled aggregation of small NPs
can give rise to micrometric clusters capable of efficiently
interacting with NIR light, allowing for photothermal therapy
and photoacoustic imaging in living mice.71–74 However, the
assembly size strongly reduces the possibility of accumulation
in extravascular targets, only allowing for intratumoral rather
than systemic injection.75,76 Alternatively, their LSPR can be
red-shifted by coating with strong absorbers such as melanin,
strongly increasing PA signal and contrast.77 In addition to
AuNPs, gold nanorods (GNRs) display a characteristic localized
surface plasmon along the longitudinal direction of the struc-
ture, which generates a sharp and intense low-energy absorp-
tion band (Fig. 4b).78–81 This can be tuned up to the NIR by
adjusting the aspect ratio of the rod, defined as its length-to-
width ratio, with much higher optical absorption coefficients
compared to organic dyes; this allows for strong contrast far
from the regions of maximum absorption of endogenous
chromophores.82–87
Besides, due to their larger size, they can accumulate via
the enhanced permeability and retention (EPR) effect, allowing
for passive tumor targeting.88–91 However, their high surface-
to-volume ratio makes them poorly photostable, and they tend
to reduce their aspect ratio upon absorption, generating the
need for a shell of dielectric material to improve the photo-
stability of the structure.92–95
The optical behavior of nanoshells has been recently
described, in which a continuous or semi-continuous layer of
gold is deposited on a nanoparticle of a dielectric material.96,97
The nanoshell thickness and radius can be tuned to make it
capable of absorbing light in the NIR with extremely high
extinction coefficients and improved photostability, allowing
for PA contrast at low concentrations.98 Also, the dielectric
core material can be chosen to provide the nanoconstruct with
additional features such as piezoelectricity and paramagnet-
ism, allowing for applications in photothermal therapy and
dual-modality imaging.99,100 In 2005, Millstone et al. first
reported the synthesis of small triangular gold nanoprisms
which exhibit strong in-plane quadrupole plasmon resonance,
resulting in an additional LSPR band at long wavelengths
(1200–1400 nm) exploitable for applications in PA imaging.101
Later, the same authors reported the implementation of their
synthesis technique, which has then allowed for fine-tuning of
Review Biomaterials Science













































































the prism edge length and therefore of the quadrupolar LSPR
band position.102 The electric field enhancement at the sharp
edges of the nanoprisms leads to higher molar extinction
coefficients compared to most other gold nanostructures,
allowing for the PA imaging of living tissues with strong con-
trast signals.103–105
Gold nanocages show similar optical properties and can be
used for drug or dye entrapment and controlled delivery,
making these systems highly advantageous for molecular
photoacoustic imaging.106–108 They are generated by the galva-
nic displacement of Ag atoms on the surface of silver nano-
particles of various shapes in the presence of gold precursor
salts, leading to hollow gold nanostructures with tunable
optical properties in the NIR, suitable for use as PA contrast
agent in vivo.109–111 Moreover, gold nanostars have been
recently reported to show characteristic absorption, which can
be tuned in the NIR by controlling the size of the nanoparticle
and the sharpness of its protuberances.112,113 Nanoscale gold
multipods, which are highly branched gold nanostructures
similar to gold nanostars, have shown good optical properties
in the near-infrared but little tunability.114,115 Therefore, their
applications as contrast agents for PA imaging are promising
but still quite limited. Fig. 5 presents characteristic TEM
images for different morphologies of gold nanostructures from
Fig. 4 Dipolar surface plasmon resonances and typical UV-VIS spectra of (a) AuNPs and (b) GNRs.
Fig. 5 Transmission electron micrograph of (a) gold nanoparticles, (b) gold nanorods, (c) gold nanoshells, (d) gold nanoprisms, (e) gold nanocages
and (f ) gold nanostars. Adapted from ref. 67.
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the literature. Extensive work for the manipulation of gold at
the nanoscale has recently led to the development of increas-
ingly complex architectures with exotic shapes, which exploit
sharp edges to red-shift their SPR absorption up to the
NIR.116,117
Quantum dots. Semiconducting nanoparticles (or quantum
dots, QDs) have found extensive application as fluorescent
probes due to their small size and interesting optical pro-
perties, which can be tuned to the NIR by choosing the appro-
priate particle size. Since their dimensions are close to or
smaller than their exciton Bohr radius, the spatial confine-
ment of the electrons in the nanostructure results in an
increased gap between valence and conduction bands and in a
size-dependent splitting of the continuous energy band into
discrete energy levels. Semiconducting nanoparticles have
shown great potential for use as contrast agents for optical
imaging due to their relatively easy synthesis and functionali-
zation and their tunable fluorescence properties (Fig. 6).118–120
The applicability of QDs as photoacoustic imaging contrast
agents is guaranteed by their high absorption cross-sections
(as high as 106 M−1 cm−1), increased photostability after pro-
longed irradiation and quantum yield comparable with most
small molecule dyes.121 Thanks to QDs’ optical properties,
their in vivo applications have been widely explored in the lit-
erature, mostly focused on PA and fluorescence imaging.122–125
However, still great effort needs to be directed towards the
investigation of QD’s pharmacokinetics (bioaccumulation, bio-
distribution, etc.) and toxicity before the application of these
nanosystems in clinics.
Other metals. Even though gold nanostructures represent
the most widely investigated metallic cores as contrast media
for PA imaging due to their unique optical properties and
chemical inertness, other nanostructured metals have been
recently exploited to image biological tissues. Either exploiting
localized surface plasmon resonance phenomena or semicon-
ducting band gaps, metal nanostructures ensure low radiative
quantum yields, increased photostability and good biocompat-
ibility. Amongst these, antimony, bismuth, cobalt, copper, pal-
ladium, silver, titanium, tungsten and uranium nanoparticles
with various shapes have shown great contrast with high
photoacoustic response in vivo recently, but their toxicity and
end-of-life are yet to be fully examined before they can find
applications in clinics.126–134
Carbon nanomaterials
Carbon nanomaterials are classified based on their dimen-
sionality, i.e. the number of spatial dimensions in which the
nanostructure develops in space:
• 0-dimensional (0D): fullerene, carbon dots and
nanodiamonds
• 1-dimensional (1D): carbon nanotubes
• 2-dimensional (2D): graphene
As is true for most nanostructured materials, the optical
properties of carbon-based nanostructures are strictly depen-
dent on their shape and size. Carbon nanomaterials are gener-
ally black, owing to a broad absorption in all the visible and
NIR, but the phenomena that generate absorption are different
in each case.135 Fullerenes (0D) behave more as molecules
than as nanostructures since their photophysical behavior in
the visible is related to the HOMO–LUMO transition of one
electron upon the absorption of a photon with the right
energy. Since they have poor fluorescence properties, they are
good candidates for the generation of high-frequency acoustic
waves.136
However, their photostability is strongly limited: upon the
absorption of NIR laser light, functionalized fullerenes gene-
Fig. 6 (a) TEM images of CdSe/ZnS QDs; (b) photograph of QDs of different diameters exposed to UV light (365 nm) and their corresponding emis-
sion spectrum; (c) representation of the exciton energy levels as a function of the size of the QD. Adapted from ref. 120.
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rate acoustic shock waves detectable by PA imaging, which
disrupt the spherical structure of the molecules and their
optical behavior.137 On the other hand, carbon nanotubes (1D)
owe their absorption properties to their semiconducting band
gap, which may vary depending on the nanotube diameter and
the chiral wrapping angle which describes how it has been
constructed by a graphene sheet.138 They also display fluo-
rescence if isolated in micelles, but their photoacoustic
response is stable enough to ensure a good photoacoustic
response in vivo.139–141 Moreover, graphene (2D) has been
reported to be a gapless semiconductor; thus it would show
weak absorption features in the NIR. However, due to the
abundance of surface heterogeneities, graphene oxide (GO)
shows strong absorption and fluorescence in the NIR
(Fig. 7).142,143 The exact origins of this behavior is still under
debate, but it is believed to be related to the electronic tran-
sition at the boundaries between GO and non-oxidized
sp2 graphene domains.144,145 Due to their promising optical
features and their easy surface functionalization and biocom-
patibilization, GO and graphene-based nanomaterials have
widely shown their potential as contrast media for PA imaging,
allowing for efficient imaging of cancer in multiple
modalities.146–148 Eventually, nanodiamonds are carbon nano-
particles in which all the atoms are sp3 carbons and no graphi-
tic-carbon is present. Their optical features include strong
absorption and weak fluorescence, which arise from local
defects in their microcrystalline structure generally induced by
other elements like nitrogen.149 On the whole, carbon nano-
materials have shown remarkable results but their absorption
in the NIR is relatively broad, thus presenting an important
challenge for spectral unmixing and distinction of the contrast
from the background; this can be limited by contrast enhance-
ment from NIR dyes attached to the carbon backbone.150–153
Still great effort needs to be directed towards the comprehen-
sion of the overall photophysical behavior of carbon nano-
materials: their limited extinction coefficients and low biocom-
patibility make them only superficially explored contrast
agents for in vivo photoacoustic imaging.
Polymeric nanostructures
Polymeric nanoparticles (PNPs) have found application in drug
delivery due to their high biocompatibility and their ability to
encapsulate and protect in their interiors drugs, dyes, proteins,
etc.154 In photoacoustic imaging, the most popular polymeric
structures contain either conjugated polymers (CPs) or por-
phyrin-related units capable of directly interacting with NIR
light thanks to their elevated π-conjugation spread throughout
the whole polymer chains.155 CPs are often referred to as semi-
conducting polymers (SPs), since their incredibly high conju-
gation degrees cause the formation of band structures and a
massive shrinking in the gap between the π and π* bands,
which resembles the features of most inorganic semi-
conductors.156 By means of microemulsion or nanoprecipita-
tion, CPs are able to self-assemble into nanostructures which
are stable and well dispersible in water, known as conjugated
polymer nanoparticles (CPNs) or semiconducting polymer
nanoparticles (SPNs). Although their extinction coefficients are
still lower than the ones of AuNPs and their absorption peak is
broad, their high photostability and chemical versatility allow
for both specific targeting and attachment of therapeutic moi-
eties. CPs are macromolecules with a conjugated π-system
spread throughout the polymeric backbone, and the polymers
are densely packed to form nanoparticles with much stronger
extinction coefficient and higher photostability compared with
small molecule dyes. Optical properties, strictly connected to
the polymeric core, can be tuned via modification of the poly-
meric backbone, combination of different polymers and
control over aggregation and surface functionalization.157–160
Because this class of contrast agents is still relatively young,
detailed biocompatibility studies aimed at showing their
potential for preclinical photoacoustic imaging still need to be
conducted.161–167 Principally, semiconducting polymers
employed for PA imaging are composed of diketopyrrolo-
pyrrole, phenothiazine, cyclopentadithiophene, fluorene, pyrrole
or thiophene monomeric units, allowing for the structural
rigidity required for efficient π conjugation (Fig. 8).168–171
Finally, non-absorbing polymeric micelles can be employed for
the encapsulation of PA active species such as lipophilic NIR
dyes and complex structures, like perylene diimide
derivatives.172–178
Essential parameters
In the process of PA contrast agent development, some key
parameters should necessarily be taken into account to allow
for clear comparison amongst different nanostructures.
• One of the most important parameters is ε or σ, the
molar absorption coefficient or absorption cross section. The
first one is the most often reported and it represents the
portion of absorbed photons with a specific wavelength in a
solution with unitary concentration, and it can be directly
Fig. 7 (a) Proposed 3D structure of GO and (b) proposed energy band
diagram of GO: larger band gaps are associated with smaller aromatic
domain size. Adapted from ref. 143.
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used to compare different contrast agents; for example, gold
nanostructures display ε between 109 cm−1 M−1 and 1011 cm−1
M−1 but most small molecule dyes have ε ≈ 105 cm−1 M−1 and
for SWNTs ε ≈ 106 cm−1 M−1.
• A second important parameter is η, the photoacoustic con-
version efficiency, which represents the fraction of photons
effectively converted into thermal energy. It is not reported
often in the literature, but it completes the information given
by ε since only photons which are efficiently absorbed and
converted can give rise to PA signals. As reported in Table 1,
some reference values for η are 23% for GNRs, 41% for Sb NRs
and 48% for TiN nanoparticles.
• The PA performances of nanostructures are often sum-
marized in the signal enhancement by the contrast agent com-
pared to pre-injection signals. This approach allows comparing
the brightness of the contrast agent directly to the surround-
ings, removing the influence of experimental variables, such
as the type of tissue or the specific instrumentation employed.
• The size of the nanostructured contrast agent generally
plays a key role in determining their optical properties but also
whether accumulation via EPR is possible or not.
• Even though the toxicity and the long-term effect of sys-
temic injection of nanostructures in living animals are rarely
investigated in preclinical studies, in vitro biocompatibility and
non-cytotoxicity studies are most often conducted prior to
in vivo experiments. Minimum or no cytotoxicity must be
observed for a nanostructure to be considered as a candidate
for PA imaging at the clinical and preclinical levels.
• Usually, the maximum absorption wavelength of the nano-
construct and the excitation wavelength employed in PA
imaging should be as close as possible to maximize the
absorption of photons and thus the PA signal. As has already
been mentioned, both wavelengths should fall in the biologi-
cal windows of the NIR region (650–950 nm and
1000–1300 nm) to reduce endogenous contrast and to maxi-
mize penetration depth.
• Finally, the injection dose is clearly useful to compare the
strengths of PA contrast in vivo, together with the time
required for contrast accumulation. It should be evaluated con-
sidering toxicity, PA performances in vitro and whether the
accumulation is expected via active or passive targeting.
Moreover, some novel multifunctional contrast agents allow
for imaging in multiple modalities; this can be done either by
covalent binding different components, each with its own con-
trast ability, or by employing compounds which are intrinsi-
cally responsive to multiple imaging techniques, allowing for
unambiguous contrast detection. Finally, some of the most
promising nanostructured contrast agents display activatable
PA activity: contrast can only be observable when some chemi-
cal modification of the nanocomposite structure triggers the
PA emission by the sonophore.
In Tables 1–3, the most important parameters are reported
for a variety of nanostructured contrast agents implemented in
in vivo PA imaging.
In vivo applications
In this section, the recent applications of the previously
described nanostructured contrast media are highlighted.
Herein, we took into consideration only the most significant
results of in vivo experiments. Firstly, the most remarkable pre-
clinical results obtained with molecular contrast agents are
rapidly summarized, and then each class of nanostructured
contrast agents is thoroughly investigated.
Small molecule dyes
In 2010, Kim et al. reported how ICG could help in the identifi-
cation of sentinel lymph nodes (SLNs) and their surrounding
vessels for breast cancer early diagnosis.179 To prove this, 5
rats underwent PA imaging in vivo after the injection of 1 mM
ICG solution. SLNs were clearly visible in the PA images
obtained, with a 6-fold signal enhancement recorded com-
pared to the system before injection. In addition, ICG fluo-
rescence was exploited for dual-modality imaging, leading to
the formulation of fluorescence images that were matching the
PA results. Later, in 2018, Wilson et al. employed antibody-con-
jugated ICG for intraoperative photoacoustic and dual fluo-
rescence imaging of breast cancer to help the surgeon during
the removal of tumoral tissues for minimizing positive resec-
tion margins.180 In 2015, Garcia-Uribe et al. employed methyl-
ene blue for the same application in a clinical trial on
Fig. 8 Monomeric units principally employed in semiconducting poly-
mers for PA imaging. The R residues can be aliphatic, to reduce close
packing of the polymers chains, or aromatic, to increase the macromol-
ecular conjugation degree.
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10 650 680 107–109
cm−1 M−1236
— 5.7× 30 nM A — Tumor contrast 76
Poly-di(carboxylatophenoxy)
phosphazene (PCPP)
200 >650 700 — — 75 µg Au M Non-significant Tissue contrast 74





PEO-b-PCL 26 800 808 37% 10× 400 µg mL−1 A Photothermal 75
Ag shell 84 756 750 — 32× 15 mg kg−1 M — Vascular imaging 116
SiO2-Gd





PEG 50 825 764–824 0.036 μm2 — 80% — — — Cerebral cortex
imaging
106
90 680–1000 700 — — 5.5× 0.6 pmol — — Tissue contrast 192





46 778 570 and 778 1.7 × 10−14 m2 — 36% 10 nM — — Tumor contrast 194
Gold
nanoprism





PEG-glucose 94 845 — — — — — Photothermal 196
PEG 110 796–911 800 — — — 200 μg mL−1 — Non-significant 105
120 830 and 530 710 — — — 744 μg mL−1 — Tumor contrast 103
SiO2 120 — 1064 — — — — — Sentinel lymph
node imaging
104
Gold nanorods PEG 40 ×
12
756 — 109–1010 cm−1
M−1237
— 2.3× 5.2 nM M Non-significant Tumor contrast 187
Gd2O2S 70 ×
40







858 800 — 2× 5 mg kg−1 M Photothermal 85
Reduced graphene-oxide 110 750 700 and 800 — 40× 2.5 nM — — Tumor contrast 231
Melanin 150 600–700 764 — — 12 mg mL−1 — None up to
2.75 mg mL−1
Tissue contrast 77





729 nm 720–740 — — 30 pM — — Stem cells
tracking
93





PLGA-b-PEG-folic acid 165 850–900 860 — — — 0.7 mg kg−1 M Non-significant Tumor contrast 191
PEG-antibody 40 710 710 — — — — — 98







PEG-integrins <20 700 670 2.02 × 10−16
m2
— 3× 0.3–12.5 nM M Photothermal Tumor contrast 197
aDetermined by TEM or DLS. It may refer to the measured hydrodynamic diameter. bMeasured molar extinction coefficient (ε) or absorption cross-section (σ). c Photoacoustic efficiency.
d Enhancement of the PA signal due to the contrast agent compared to the background or control sample. e Activatable (A) or multimodal (M) probes. f Collects the evaluations on particle tox-







































































































































e Toxicity f Application Ref.
Pt–Cu alloy NPs PVP 100 Broad 808 — — — 1.34 mg kg−1 M 300 μM Tumor contrast 207
Bi nanoparticles PEG-Gd3+ 46 700–900 680–900 — — — 10 mg mL−1 M Non-significant Tumor
theranostics
134





Co9Se8 nanoplates PAA 100 broad 808 — — — — M 120 μg mL−1 Tumor contrast 204
MnMoOx
nanorods








PEG 30 700 700 28.6% 2.5× 1 mg mL−1 M — Tumor contrast 209
Pd nanosheets PVP 16 790 790 — — 3.4× 0.8 mg mL−1 — — Tumor contrast 129
Silver nanoplates PEG 25–220 550–1080 740–940 — — — 1012 nanoplates
in 200 μL





SiO2-BSA 200 680 680–950 — — 70% 20 μM M — Sentinel lymph
node imaging
211
TiS2 nanosheets PEG 100 800 808 26.8 L g
−1
cm−1
— 4× 2 mg mL−1 — — Tumor contrast 131
Titanium nitride
NPs
PEG 20 600–1000 808 28.6 L g−1
cm−1
48% 1.3× 2 mg mL−1 M — Tumor contrast 212
WS2 nanosheets PEG 50–100 700–1000 700 23.8 L g
−1
cm−1
— 6× 5 mg mL−1 M — Tumor
theranostics
132
Upconversion NPs α-Cyclodextrins 29 — 980 — — — 0.5 mg mL−1 — None up to
0.2 mg mL−1
Tissue contrast 199
Bi2Se3 nanoplates PVP 70 broad 1064 — — 19.6× 15.26 mg mL





Ti(OTs)4 2 680 680 22.2 L g
−1
cm−1
— 6× 200 μg in 100 μL — Non-significant Tumor contrast 201
PEG 22 808 680 2.1 L g−1
cm−1
— — 2 mg mL−1 — Photothermal Tumor
theranostics
202
Uranium PLGA 335 848 910 — — 1.8–7.4× 0.38 nM (2.75 mg
mL−1)
— — Tissue contrast 133
CuS nanoparticles PEG 11 990 1064 2.6 × 107
cm−1 M−1





Citrate 20 680 and 930 680 and 930 — — — 0.8 mg mL−1 A Non-significant Tumor contrast 123
Cu2−xSe
nanocrystals
DSPE-PEG 7.6 1150 900 2 × 10−18
m2





CuInS/ZnS DSPE-PEG 25 and
80
650–750 — — 11.6% — 2 mg mL−1 M Non-significant Tumor
theranostics
203





aDetermined by TEM or DLS. It may refer to the measured hydrodynamic diameter. bMolar extinction coefficient (ε) or absorption cross-section (σ) measured for the nanosystem.
c Photoacoustic efficiency. d Enhancement of the PA signal due to the contrast agent compared to the background or control sample. e Activatable (A) or multimodal (M) probes. f Collects the





































































































































e Toxicity f Application Ref.
Carbon nanotubes Pluronic 2 Broad 740–820 5 × 103
M−1 cm−1
(ref. 238)
— 5× 0.5 mg mL−1 M — Sentinel lymph
node imaging
140
PEG 80–100 Broad 808 — 5× 2 mg mL−1 — Non-significant Tumor contrast 217
PEG-RGD 50–300 Broad 710–780 — 80% 50 nM — Non-significant Tissue contrast 216
Graphene BSA 70 Broad 808 nm — — 55% 1 mg mL−1 — Non-significant Tumor contrast 146
Fullerenes on SiO2 PHF 50–100 Broad 785 nm — — 100% 0.45 mg mL
−1 — Non-significant Tumor contrast 218
Carbon nanoparticles Citric acid-antibody 12 425 680–760 — — — 7 mg mL−1 — Photothermal Tumor
theranostics
220
— 70 820 820 — — 9.2× 90.3 μg mL−1,
0.238 nM
— Non-significant Tissue contrast 221
PEG 7 510 510 — — 60% 25% vol. 100 μL — Non-significant Sentinel lymph
node imaging
219
Polypyrrole NPs PEG-Gd3+ 70 Broad — — — 3× 5 mg mL−1 M Photothermal Tumor
theranostics
163
PVA 46 Broad 808 2.4 × 1010
cm−1 M−1






40 660–700 700–820 5.0 × 107
cm−1 M−1
— 13.3× 50 μg M Non-significant ROS imaging 222
120–160 700–825 600–1000 250 cm−1 L
g−1
— −1 1.6 μg in 10 μL — Non-significant Vascular
imaging
162
DSPE-PEG-folate 50 700–850 700–900 — — 4× 0.3 mg mL−1 — — Tumor contrast 160
PEG-phospholipid-Gd3+ 110 670 680 — — 3.5× 0.1 mg mL−1 M Photothermal Tumor
theranostics
157
PEG-b-PPG-b-PEG 55 840 750 — — 2.6× 0.1 mg mL−1 — Photothermal Tumor
theranostics
158





PEG-b-PPG-b-PEG 11–54 744–253 750–1064 — — 1.5× 6 mg mL−1 — None up to
0.5 mg mL−1
Tissue contrast 226
DSPE-PEG 68 809 1000–1200 — — 3.4× 50 μg mL−1 M None up to
150 μg mL−1
Tumor contrast 171
PEG-b-PPG-b-PEG 40 616–665 680 — — 4.7× 30 μg in 120 μL — Non-significant Tumor contrast 164
SiO2-PEG 18 680–860 680 — — 1.5× 0.1 mg mL




DSPE-PEG 45 748 710–850 76 mL
(mg cm)−1
— 5.3× 30 μg in 120 μL — Non-significant Tumor contrast 213
aDetermined by TEM or DLS. It may refer to the measured hydrodynamic diameter. bMolar extinction coefficient (ε) or absorption cross-section (σ) measured for the nanosystem.
c Photoacoustic efficiency. d Enhancement of the PA signal due to the contrast agent compared to background or control sample. e Activatable (A) or Multimodal (M) probes. f Collects the

























































































































humans.181 Study participants have been subcutaneously
injected with MB in the same breast area as their primary
breast cancer. Patients underwent noninvasive PA imaging at
the injection site. To correctly differentiate the contrast from
the surrounding vessels, PA images have been acquired at two
different wavelengths (650 and 1064 nm) and compared,
obtaining signal enhancement factors of 1.75 on SLNs in the
tumor region. As has already been said, SMDs suffer from
some important drawbacks, which drastically limit the employ-
ability of molecular contrast agents in their free form. These
are (1) fast clearance from the circulatory system due to the
immune response of the organism, (2) concentration-depen-
dent optical behavior, caused by intrinsic lipophilicity of poly-
conjugated chromophores, (3) small optical absorption wave-
length and low extinction coefficients. Because of this, the
attention of scientific research has been directed towards the
employment of specifically engineered nanostructured con-
trast agents, which can overcome the intrinsic limitations of
SMDs.
It is worth reporting that the possibility of exploiting
different phenomena for the generation of photoacoustic
signals upon laser exposure has been lately explored. In par-
ticular, in 2012, Wilson et al. proposed that laser-induced
vaporization of perfluorocarbon nanodroplets could induce PA
contrast in biological systems.182 Even though this could
provide efficient PA contrast in vivo, the system requires the
employment of small molecule dyes as photoabsorbers, with
all the limitations associated with dye-based PA contrast.
Metal and semiconducting nanoparticles
Gold. Due to their small size, gold nanoparticles have LSPR
bands in the visible, up to 600 nm. To adapt them for PA
imaging in vivo, AuNPs need to form stable aggregates to red-
shift their plasmon band.183,184 Otherwise, the PA penetration
depth for short wavelengths limits their application to super-
ficial targets such as rat brains. In 2012, Kircher et al. pre-
sented a Magnetic–Photoacoustic–Raman (MPR) triple
modality imaging nanoparticle for brain tumor imaging, both
in vitro and in living mice.185 Their probe was built as a gold-
core silica-shell SERS nanoparticle decorated with paramag-
netic Gd3+ ions, allowing for picomolar sensitivity of MRI, PA
imaging and SERS imaging of glioblastoma in vivo (Fig. 9).
Since the nanoconstruct displayed its optical absorption
maximum at 550 nm due to its spherical gold core, the
authors implemented a 525 nm laser in their home-made PA
imaging setup. In particular, they obtained significant PA con-
trast at concentrations as low as 1.22 pM in phantoms, and
they observed a 75% increase of the photoacoustic signal of
the tumor after tail vein injection of MPRs in tumor-bearing
mice. No accumulation was observed in the healthy tissues,
allowing for the identification of tumor borders to facilitate
resection.
Lately, Cheng et al. reported the fabrication of a light-trig-
gered assembly of gold nanoparticles which could serve as a
contrast agent for PA imaging of tumors.186 The nanoparticles
described were composed of a 20 nm gold core functionalized
with diazirine moieties on covalently-linked PEG chains. Upon
irradiation with 405 nm laser light, diazirine groups cross-link,
leading to covalent aggregation. The surface plasmon bands of
gold cores shift to the NIR, leading to aggregates with photo-
acoustic efficiency as high as 78.8%, with negligible cytotoxicity
to 4T1 cells up to 200 µg mL−1. After the assessment of the
feasibility of laser-induced aggregation in vivo, the authors
injected 100 µL of 2 mg mL−1 of AuNPs in the tail vein of
female nude mice bearing 4T1 tumors. Tumors have been
exposed to 405 nm laser light for 25 s to induce aggregation at
the tumor site, followed by PA imaging. Compared to control
animals, images obtained from tumor-bearing mice showed
increased PA contrast at the tumor site.
Recently, gold nanorods have found various applications
on the basis of their photoacoustic response to exploit
them for tumor detection in vivo. In 2012, Jokerst et al.
exploited localized surface plasmon for SERS (surface-
enhanced Raman scattering) on the GNR surface: dual-
modality SERS and PA gold nanorods have been used to image
subcutaneous ovarian tumor xenograft models (OvCA) in vivo,
Fig. 9 In vivo triple modality imaging of MPR nanoparticles. (a) MRI, PA
and Raman 2D axial images before and after injection of MPRs, (b) 3D
rendering of MRI and PA signals, and their overlay, showing good tumor
contrast, (c) quantification of MRI, PA and Raman signal intensity before
and after the injection of the nanoconstruct. Notwithstanding the limit-
ations in PA imaging penetration depth due to the short excitation wave-
length employed, thanks to glioblastoma superficiality strong PA con-
trast has been obtained; adapted from ref. 185.
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showing how GNRs could offer both photoacoustic signals for
diagnostics and tumor visualization and optical SERS for
image-guided resection.187 For this purpose, GNRs have been
prepared with the absorption band in the NIR for PA signals
and then functionalized with an IR laser dye and thiol-PEG to
ensure an intense SERS response. By means of their photo-
acoustic response, intravenously injected GNRs have been
shown to accumulate by the EPR effect in 2008, HEY and
SKOV3 OvCA tumor cells, allowing for efficient tumor visualiza-
tion. On the other hand, SERS has been exploited for tumor
edge identification and for image-guided resection on tumor
xenografts from the 2008 cell line OvCA model.
Guo et al. recently reported the preparation of gadolinium
oxysulphide-coated gold nanorods as dual-modality contrast
agents for PAI and MRI, employing the strong MRI contrast of
gadolinium, which is strongly paramagnetic due to its seven
unpaired electrons.188 GNRs have been prepared with the pre-
viously described seeded-growth method, and coating with
gadolinium oxysulphide has been performed via a one-step
process with Gd nitrate as a gadolinium source in the presence
of ascorbic acid (AA) and thioacetamide (TAA) at 80 °C. Then,
NPs have been further modified with polyvinyl alcohol (PVA)
for stabilization. Increasing the Gd2O2S shell thickness could
increase the effective dielectric constant surrounding the plas-
monic core, resulting in a red-shift of the longitudinal LSPR
mode. The PA and MRI response of the nanosystem has been
tested both in vitro and in vivo. Once the feasibility of the study
was proved, GNRs@Gd2O2S has been intratumorally injected
into Hep G2 tumor-bearing BALB/c nude mice as a model for
in vivo PAI/MRI dual-modal imaging. A 4-fold increase in PA
signal and a 2-fold increase in MRI contrast have been
observed after injection, demonstrating the effect of the
system as a dual-modality contrast agent.
An additional interesting application of GNRs in photo-
acoustic imaging has been described by Du et al.189 The
authors demonstrated the possibility of building a nanoplat-
form by assembling GNRs on the surface of a DNA-origami
nanostructure. The nanostructured hybrid, which combines
the well-known optical properties of GNRs with the enhanced
passive tumor targeting and long-lasting effects of DNA nano-
structures, has been exploited as a unique probe and an
efficient contrast agent in PAI, generating intense signals at
very low concentrations. PAI has been performed on breast-
tumor xenografted mice in which DNA-GNRs nanoplatforms
have been intravenously injected, revealing enhanced tumor
accumulation compared to bare GNRs. Accumulation of gold
via EPR effect has been observed to be slower but more persist-
ent with DNA-GNRs compared to bare GNRs, giving rise to
elevated tumor/muscle contrast ratio even 24 h post-injection
(Fig. 10).
In 2018, Chen and co-workers developed polyethyl-
eneimine-modified GNRs (GNRs-PEI) connected to a Fuel
Improved microRNA Explorer (FIRE) capable of distinguishing
tumor cells from healthy tissues efficiently.190 Their nano-
construct was able of carry out active targeting, thanks to the
detection of microRNA-21 strands, upregulated in cancer cells,
by designing a smart fluorescence quenching approach in
which the fluorescence signal was expected to be much stron-
ger for tumor tissues than for the healthy one. Their platform
demonstrated good tumor inhibition efficacy in vivo via both
Fig. 10 (a) Gold distribution and the corresponding oxygen saturation maps before intravenous injections of GNRs and GNRs-DNA in 4T1-tumor-
bearing mice. (b) GNRs and DNA-GNRs distribution after intravenous injection, (c) 3D rendering of the tumor region 24 h post-injection and (d) PA
contrast ratio between tumor and muscle for GNRs and DNA-GNRs as a function of time after the injection. Adapted from ref. 189.
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fluorescence imaging and photoacoustic imaging-guided
photothermal therapy. To evaluate PA contrast, 100 µL of
0.8 mg mL−1 GNRs-PEI solution have been intratumorally
injected into tumor-bearing mice, revealing strong PA signals
that can be easily differentiated from the background at the
tumor site.
Recently, we described the fabrication of a core–shell com-
posite nanomaterial in which a paramagnetic Fe3O4 core has
been covered with a layer of silica on which a gold shell has
been grown.191 The so-called Fe3O4@SiO2@Au NPs have been
entrapped in polymeric micelles to protect the metallic core
from the biological environment; then they have been further
conjugated to folic acid to ensure specific targeting to IGROV
ovarian cancer cells. The nanoconstruct, which displayed a
hydrodynamic radius of about 165 nm, had its optical absorp-
tion maximum between 850 and 900 nm with a high molar
absorption coefficient and no fluorescence properties; this
made the core–shell system a good candidate for the multi-
spectral PA imaging of tumor models in vivo. Xenograft tumor-
bearing mice were systemically injected with folic acid-conju-
gated Fe3O4@SiO2@Au NPs at concentrations of 8 mg Au per
kg, and the tumor was imaged at 860 nm 4 h post-injection for
maximum sensitivity. The magnetic core allowed for MRI,
making the core–shell system a sensitive dual-modality
imaging platform for the detection of ovarian cancer.
As previously introduced, gold nanocages can represent
powerful theranostic platforms, and they can give rise to high
PA signals, thanks to their surface plasmon features. In 2014,
Jeon et al. described the use of NIR-absorbing gold nanocages
to image the murine bladder in vivo.192 PEGylated gold nano-
cages (λ = 700 nm) have been prepared by galvanic replace-
ment reaction on silver nanocubes and covalently linked to
PEG-SH for biocompatibilization. After transurethral injection
of a 2 nM solution of nanocages, rats underwent non-invasive
PA cystography and displayed a 22.4× enhancement of PA
signal compared to the control sample. Moreover, no more
signal could be observed in the bladder after 24 h, suggesting
that the injected nanosystem was not retained in the bladder
but washed away by the urine.
Sakthi Kumar and co-workers recently described the pro-
duction of gold nanocages for the first contrast-based PA
imaging of the eye.193 The nanosystem was produced by an
ultrafast microwave-assisted procedure, which led to nano-
cages with a uniform edge size of about 50 nm, showing
strong optical absorption properties at 900 nm. After the evalu-
ation of the PA contrast potential in polyethylene tubes for the
obtained nanostructure, nanocages have been injected right
above the iris of an enucleated porcine eye, showing a PA con-
trast enhancement of 50% and thus leaving the open possi-
bility of surface modification of nanocages to enable active tar-
geting for specific eye diseases (Fig. 11).
Kim et al. have reported the applications of gold nanocages
for molecular PA imaging of melanomas.194 Nanocubes, pre-
pared by the traditional galvanic replacement method, have
been conjugated with [Nle4,D-Phe7]-α-melanocyte-stimulating
hormone in order to bind to α-MSH receptors overexpressed in
melanomas. The authors injected 100 µL of 10 nM targeted Au
nanocages into the tail vein of mice; 6 h later, the mice under-
went PA imaging at the tumor site with a 778 nm pulsed laser.
They observed 300% PA signal enhancement at the tumor site
compared to the signal in mice injected with the same amount
of untargeted nanocubes, showing both the efficacy of their
active targeting system and the efficiency of gold nanocubes
for PA contrast. In addition, PA has been employed to image
the vasculature surrounding the tumor, obtaining more infor-
mation about the melanoma state. This has been performed
by tissue laser excitation at 570 nm.
In 2016, Bao et al. have shown, in their work, how peptide-
conjugated gold nanoprisms (AuNPrs) could serve as a PA con-
trast agent for tumor angiography and in situ imaging of a
murine orthotopic gastric carcinoma model.195 By scanning
the tumor site with a PA setup at 710 nm, the tumor vascula-
ture has been visualized before and 1, 3 and 6 h after tail-vein
injection of peptide-coated PEGylated AuNPrs at 1 mg mL−1
concentration, showing retention of good contrast at the
tumor site. In parallel, antibody-conjugated AuNPrs have been
used to image gastric cancer by photoacoustic detection of the
accumulation of the gold nanostructure. Since most PA photo-
absorbers have potential application in photothermal therapy
(PTT), AuNPrs have been exploited to directly measure by PA
imaging the reduction in tumor size after prolonged exposure
to continuous 980 nm laser light. Their results clearly showed
triangular gold nanoprisms as two molecular probes with high
sensitivity contrasts and therapeutic agents for tumor detec-
tion in vivo, which represent a safe theranostic nanoplatform
Fig. 11 (a) Photograph of the enucleated porcine eye. (b) Schematic
representation of the eye parts. (c) PA images acquired before and after
the injection of nanocages in four different eye samples, showing
increased PA contrast. (d) PA contrast enhancement for the four injected
samples. Adapted from ref. 193.
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as confirmed by the histological analysis performed on organ
tissues after 14 days from the injection.
The same year, Han et al. described the fabrication of
glucose-functionalized gold nanoprisms with improved cellu-
lar uptake and cytotoxicity in cancer cells.196 In comparison
with target-less nanoparticles, glucose conjugation helped
towards the accumulation of photoabsorbing AuNPrs in cancer
cells. The authors injected 100 µg of 1 mg mL−1 of glucose-
conjugated PEGylated nanoprisms into MGC-803 cell tumor-
bearing nude mice. PA imaging of the tumor showed great
contrast enhancement, increasing with time post-injection by
excitation at 778 nm. A weaker tumor profile was observed
after the injection of untargeted PEGylayed nanoprisms, com-
pared to the control image obtained after the injection of PBS
solution. The authors explored whether their nanoconstruct
could serve as a photothermal therapy agent, showing remark-
able results and drastic tumor growth inhibition.
Cheng et al. firstly reported in 2014 the production of
20 nm gold nanotripods as a contrast agent for in vivo photo-
acoustic imaging.197 Gold nanotripods displayed cross-sections
of the order of 10−18 m−2 at 700 nm, generating 33% more con-
trast than the same mass of gold nanorods. As a proof-of-
concept, the authors conjugated cyclic Arg-Gly-Asp-D-Phe-Cys
(RGDfC) peptide to PEGylated nanotripods to demonstrate the
effective contrast in vivo by active targeting. PA imaging has
been performed at 700 nm on living mice after the injection of
100–200 µL of targeted gold nanotripods in PBS, 0.5 to 4 h
post-injection. Compared to control experiments, the nano-
structure could provide more than 3 times higher PA contrast.
Moreover, the signal intensity has been observed to respond
linearly to variations of the injected concentration (Fig. 12).
Intravenous injection of nanotripods displayed increased con-
trast at subnanomolar, generating images that well correlated
with the corresponding PET studies.
Liang et al. reported in 2015 the preparation of highly
branched gold nanoparticles named gold nanostars (GNSs)
displaying strong PA contrast.198 The nanostructure displayed
an absorption maximum at about 635 nm and the hydro-
dynamic radius has been measured to be around 100 nm.
Due to their promising properties, anti-CD44 and anti-
CD44v6 monoclonal antibodies have been conjugated to
PEGylated nanostars, to evaluate the interaction between the
nanoprobes and gastric cancer stem cells (GCSCs). To evaluate
PA contrast in vivo, the authors intravenously injected 150 µL
of gold 0.867 mg mL−1 as conjugated gold nanostars, and
monitored the PA signal intensity at the tumor site over time.
Results showed a contrast enhancement by a factor 4.7 and 2.5
for nanostars targeted with CD44v6 and CD44, while only a
factor of 1.75 was observed after the injection of untargeted
GNSs, showing the reliability of both the contrast from nano-
stars and the effectiveness of the active targeting.
In summary, gold nanostructures can be considered as
some of the most promising nanostructured contrast agents
for PA imaging, offering wide shape- and size-dependent
absorption behaviour, high photoacoustic conversion efficien-
cies and well known biocompatibility. They also show high
extinction coefficients thanks to the localized surface plasmon
resonance (LSPR) phenomena, which allows the employment
of low injected concentrations to achieve efficient contrast
in vivo. Moreover, since their surface chemistry is well known
and deeply explored in the literature, gold nanostructures can
be easily functionalized either with active targeting agents or
with additional functional probes, which allows their employ-
ment for tumor imaging in multiple modalities, such as MRI,
Fig. 12 (a) PA images of agar phantoms containing U87MG cancer cells exposed to RGD-conjugated gold nanotripods at different cell concen-
trations and for different excitation wavelengths. (b) Linear correlation between photoacoustic signal and the number of treated cells in the
phantom. (c) Optical picture of a treated mouse, with injection sites highlighted by the injected concentration. (d, e) PA imaging of the area subcu-
taneously injected with the nanoconstruct, showing the different injection sites with different intensities. (f, g) 3D volume rendering of PA (green)
and US (brown) signals recorded. (h, i) Linear correlation between the injected concentration and photoacoustic signal in vivo. Adapted from ref. 197.
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CT, PET, SERS and optical imaging. Amongst other gold nano-
structures, the most promising results have been obtained
with gold nanorods (GNRs): their longitudinal LSPR can be
finely tuned in the synthesis step throughout the NIR, allowing
us to specifically design GNRs to overcome the different
endogenous contrast in different biological tissues.
Quantum dots and rare-earths
Upconversion nanoparticles (UCNPs) are Yb3+ and Er3+ co-
doped NaYF4, which are characterized by efficient NIR-to-visible
optical conversion, thanks to energy transfer processes between
Yb and Er. In 2014, Maji et al. described how luminescence
from UCNPs could be quenched to ensure high PA contrast
in vivo upon irradiation at 980 nm.199 Lipophilic UCNPs dis-
played the characteristic emission bands from Er3+. By encapsu-
lating the doped nanoparticles in α-cyclodextrins, hydrophilic
UCNPs (UC-α-CD) have been obtained. Hence, the quenching
effect of water as a solvent strongly reduced the luminescence of
the particles in favour of a remarkable PA contrast enhance-
ment. PA images have been acquired before and 35 min after
the intravenous injection of 250 µL of UC-α-CD at 500 µg mL−1
concentration. Results showed signal retention enhancement at
the kidney while the cytotoxicity tests revealed the non-toxicity
of the nanostructure up to 200 µg mL−1, supporting the applica-
bility of rare-earth doped semiconducting nanoparticles in
photoacoustic imaging by effective water quenching.
The same year, Sheng et al. reported the synthesis of rare-
earth doped NaYF4 with different morphologies for similar
applications.200 These authors intravenously injected NaYF4:
Er,Yb with different surface stabilizers in living mice, declaring
a signal enhancement of 2.7 times the background by exci-
tation at 975 nm.
Lately, Sun et al. described how TiL4-coordinated black
phosphorus (TiL4@BP) quantum dots could serve as a contrast
agent for in vivo PAI of cancer, as an improvement of a pre-
vious study from 2016.201,202 The QDs’ average size was
2.8 nm, and they displayed molar extinction coefficients of
22.2 L g−1 cm−1 at 680 nm, 3.6 times higher than the one
measured for GNRs when compared on a per mass basis. To
evaluate the effective PA contrast that could be generated
in vivo, 200 µg of TiL4@BP QDs have been intravenously
injected into eight MCF-7 tumor-bearing Balb/C nude male
mice. PA images have been obtained by summing the PA
response acquired from five laser pulses at 608 nm in 15 nm
steps before and 0.5 to 48 h post-injection. The obtained
images demonstrated the effective accumulation of TiL4@BP
QDs in the tumor, with a maximum contrast obtained 4 h
post-injection and still weakly retained after 48 h from the
administration. No relevant cytotoxicity has been detected
in vitro.
Lv and coworkers reported in 2016 the NIR-emission pro-
perties of CuInS/ZnS (ZCIS) QDs for both tumor fluorescence
and photoacoustic imaging.203 The authors prepared two
similar nanosystems with different sizes (25 and 80 nm) to
evaluate differences in the diffusion profiles and tumor
uptake. The QDs displayed strong optical absorption at
650–750 nm, suggesting a potential PA imaging ability.
Multispectral Optoacoustic (MSOT) imaging was performed
between 680 and 900 nm at different time steps after the intra-
venous administration of 200 µL of 2 mg mL−1 ZCIS solution
in nude mice bearing 4T1 tumors. The experiments revealed
size-dependent particle accumulation and cleavage at the
tumor site: smaller particles have longer tumor retention
times and tumor uptake compared to the bigger ones (Fig. 13).
Fig. 13 (A) In vivo MSOT imaging of 4T1 tumor-bearing nude mice injected with ZCIS of 25 nm (NMs-25) or 80 nm (NMs-80) at different time steps
after the injection, revealing higher contrast at the tumor site for smaller particles. (B) Average MSOT signal intensity at the different time steps.
Adapted from ref. 202.
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In addition, fluorescence from the QDs allowed for fluo-
rescence imaging, which confirmed the results from PA
imaging. Furthermore, the ability of ZCIS to mediate photo-
induced tumor ablation was evaluated with success.
To sum up, nanosystems containing or composed of this
exotic class of materials display good photoacoustic contrast
and most of them can be also employed for fluorescence
imaging due to their widely reported photoemission behav-
iour. There are still few examples of their application in PA
imaging; great effort still needs to be directed towards the
study of their bioaccumulation and toxicity; notwithstanding
their excellent and tunable photophysical properties, quantum
dots and rare-earth nanoparticles still suffer from poor bio-
compatibility and high production costs which, nowadays,
drastically limit the potential translation of this class of nano-
systems into the clinics.
Other metals. In 2015, Song and co-workers presented a
paper on Co9Se8 nanoplates for PA/MRI dual-modality imaging
and photothermal therapy (PTT).204 Poly(acrylic acid) functio-
nalized cobalt chalcogenide nanoparticles (PAA-Co9Se8 nano-
plates) are reported to display strong NIR absorption pro-
perties and increased biocompatibility. Also, due to cobalt
paramagnetism, the nanoconstruct could efficiently serve as a
MRI contrast agent. The large surface area of nanoplates
allowed for increased drug loading, tested with doxorubicin
(DOX) as a proof-of-concept. PA imaging was performed with
an 808 nm pulsed laser after the injection of PAA-Co9Se8 nano-
plates into HepG2 liver tumor-bearing mice, showing a strong
photoacoustic response around the tumor region, while only
major vessels could be identified before the injection. MRI
images displayed clear contrast enhancement at the tumor site
after injection, as in PA imaging. Moreover, positive results
have been obtained from the release profiles of loaded DOX
and a drastic reduction in tumor growth after photothermal
treatment of nanoplate-injected mice. Even though the
employment of cobalt in the nanostructure allows for simul-
taneous PA and MRI of the tumor region, the authors did not
evaluate the photothermal behaviour of the nanoplates,
making it hard to compare their contrast performances with
contrast media of different nature. However, the broad NIR
absorption of PAA-Co9Se8 nanoplates makes them a versatile
contrast agent, allowing us to adapt the PA excitation wave-
length to the different biological transparent windows of
different biological tissues.
Lately, Gong et al. described the production of PEGylated
MnMoOx nanorods as a PA probe for the identification of glu-
tathione (GSH) in vivo.205 GSH is an easily oxidizable tripeptide
with good antioxidant properties. Their nanoprobe was
capable of actively targeting without the need for any surface
modification but exploiting the chemistry of the core elements
themselves. In fact, GSH was able to reduce MoVI to MoV
efficiently, thus causing the disruption of the non-absorbing
nanorod and providing contrast from strongly absorbing nano-
dots. Since GSH is overexpressed in various tumor tissues,
their system was able to provide efficient PA contrast in vivo at
the tumor site by excitation at 830 nm, revealing contrast capa-
bility triggered by the tumor itself. Moreover, the release of
Mn2+ ions during GSH activation allowed for the possibility to
employ T2-weighed MRI to co-detect tumor localization. To
further study the potential of the nanosystem for GSH detec-
tion, mice bearing 4T1 tumors were intravenously injected
with PEGylated MnMoOx, revealing 2× PA signal enhancement
at the tumor site compared to healthy muscle tissue. This
work reports a smart approach for the generation of tumor-
induced PA and MRI contrast, since it is the tumor itself that
chemically modifies the small nanorods through the over-
expression of GSH. Here, intravenous injection of the nanorod
dispersion allows for PA contrast at the tumor site without the
need for any active targeting; however, the conjugation of
active targeting species such as antibodies, nucleic acids or
small targeting molecules could, in principle, increase the
specificity of the contrast and reduce the distribution of
manganese- and molybdenum-based compounds in the body.
Pan et al. have reported the synthesis of copper neodecano-
ate nanoparticles for PA imaging of SLNs.206 In their work, the
authors for the first time produced a copper-based contrast
agent for SLN detection by PA imaging in vivo. Their nanocon-
struct was an 80 nm wide self-assembled copper neodecanoate
nanoparticle encapsulated in phospholipid micelles, which
displayed an optical absorption maximum at λ = 603–746 nm.
The absorption is believed to originate from crystal field split-
ting of Cu2+-neodecanoate complexes, and it has been thought
to be exploitable for PA imaging. After the administration of
1 mg mL−1 nanoparticle suspension in living mice, bright PA
contrast was observed immediately and 60 min post-injection.
A signal enhancement of 500% has been measured for a 20%
colloidal suspension of nanoparticles, much faster accumu-
lation rates compared to GNRs. However, compared to most
other reviewed nanostructured contrast agents, copper neode-
canoate nanoparticles display a quite blue-shifted absorption
(below 800 nm) which can severely limit the PA response of
the nanosystem in deep tissues.
In 2016, Zhou et al. developed dendritic Pt–Cu alloy nano-
particles (DPCNs) as multimodal imaging and guided chemo-
photothermal therapy (CTP).207 Furthermore, they demon-
strated that their construct could serve as light and a pH-trig-
gered drug delivery platform, and the promising photothermal
properties of DPCNs suggested their implementation for PA
imaging and CTP. Thanks to their elevated surface area, den-
dritic structures can adsorb an increased amount of small
molecules, improving their performances in drug loading
capacity. Firstly, negligible cytotoxicity was observed up to
300 µM; therefore, tumor-bearing mice were intravenously
injected with DPCN at a dose of 1.34 mg kg−1 to undergo PA
imaging analysis. Imaging results showed efficient nano-
particle accumulation in the tumor and strong contrast
enhancement at different time steps after injection (0 to 24 h).
Lately, Park et al. reported the novel synthesis of Bi2Se3
nanoplates for long-wavelength PA imaging of sentinel lymph
nodes in vivo.208 Thanks to their absorption after 1000 nm,
and thus the employment of low-energy highly penetrating
radiations, PA imaging of deep tissues has been explored. After
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the complete evaluation of the photophysical properties of the
exotic material, PA imaging contrast has been first evaluated
ex vivo in deep chicken tissues by excitation at 1064 nm (ND:
YAG laser); then it has been employed to image small animals.
In parallel, 50 μL of 15.26 mg mL−1 nanoplates have been
transurethrally administered to Balb/c mice for contrast-based
cystography; 200 µL of the same solution has been orally given
to mice for the imaging of the gastrointestinal tract and an
additional 20 µL have been subcutaneously injected to image
sentinel lymph nodes. For all the investigated tissues, strong
PA signal enhancement was observed, with high signal-to-
noise ratio and reduced cytotoxicity. In this study, the authors
reported very strong PA signal enhancement both in the
bladder and at the lymph nodes, but it should be noted that
the injected concentration is relatively high (over 15 mg mL−1);
thus, detailed toxicity and bioaccumulation studies should be
performed to evaluate the impact of high concentrations of
bismuth and selenium on the health of treated mice.
Chen et al. described in 2014 a novel nanostructured thera-
nostic platform based on core–shell Pd@Au nanoplates for
in vivo PA imaging, CT imaging and PTT.209 Hexagonal palla-
dium nanosheets with an average diameter of 26 nm were
covered with a tunable shell of gold for optical absorption pro-
perties in the 600–1300 nm region. To quantify PA contrast
from Pd@Au nanoplates, Balb/c mice were injected with
300 µL of 1 mg mL−1 PEGylated nanoplate solution and PA
images have been recorded at 1 to 24 h post-injection. After
prolonged accumulation by the EPR effect, nanoplates gener-
ated contrast 4 times brighter at the tumor site than the tissue
before the injection (Fig. 14).
In 2012, Homan et al. first reported the application of silver
nanoplates as a contrast agent for molecular PA imaging.210
The authors prepared triangular Ag nanoplates by a seeded-
growth method with tunable LSPR from the visible up to the
NIR. To detect by PA imaging the active-targeted accumulation
of nanoplates in tumors, an anti-epidermal growth factor
receptor (a-EGFR) antibody was conjugated on PEGylated
nanoprisms, successively injected into the tail vein of Nu/Nu
transgenic mice with xenograft human pancreatic cancer
grown orthotopically. At 4 h post injection, the maximum
accumulation in the tumor was observed by monitoring PA
signal over time. Overall, this study revealed the applicability
of Ag nanoplates as a PA contrast agent and their potential use
for bioimaging and sensing.
Lately, Cha et al. have described the preparation of silica-
coated silver bumpy nanoshells (AgNSs@SiO2) for SERS and
PA imaging of SLNs in vivo.211 AgNSs have displayed strong
scattering properties in the NIR with an absorption peak at
680 nm, and higher SERS enhancement compared to gold
nanorods or nanospheres. For this reason, AgNSs have been
first labeled with various Raman probes and then embedded
in SiO2 shells and surface-stabilized with bovine serum
albumin (BSA) for PA imaging at 680 nm and SERS. PA has
been performed on female rats, enabling contrast at the SLN
3.3 and 3.8 times more intense than the response of hemo-
globin from the surrounding vessels at 40 and 160 min of the
injection, respectively. SERS results confirmed strong accumu-
lation on SLN in vivo. Nano-silver has been widely studied in
the last few decades thanks to its well-known biocompatibility
and antibacterial properties; herein, it has been demonstrated
how, similarly to gold, its longitudinal LSPR can be finely
tuned in the NIR for application in PA imaging and photother-
mal therapy. However, nanostructures of this metal require
larger sizes and more complex shapes to achieve high absorp-
tion coefficients in the biological windows.
In 2017, He et al. documented the application of titanium
nitride nanoparticles (TiN NPs) as a novel theranostic platform
for PA imaging and PTT.212 Compared to gold and silver, the
LSPR of titanium is significantly red-shifted and strong
absorptions in the NIR can be obtained without the need for
complex architectures.213 The authors obtained 20 nm par-
ticles with broad absorption in the NIR and poor cytotoxicity
in vitro and suggested their application in PA imaging and
PTT. For these reasons, tumor-bearing mice were injected with
PEGylated TiN NPs in their jugular vein and PA imaging was
performed at the tumor site. PA images showed 150% signal
enhancement at the tumor site 24 h after the injection,
suggesting effective tumor accumulation. PTT results con-
firmed the potential of Pt as a theranostic platform for PA
imaging.
Carbon nanomaterials
Basic work on the application of single-walled carbon nano-
tubes (SWNTs) for PA imaging was performed by de la Zerda
et al. between 2008 and 2012.214–216 Firstly, it has been
described how RGD-conjugated carbon nanotubes could serve
as a contrast agent for PA imaging of tumors in vivo. They
obtained SWNTs of 1–2 nm in diameter and 50–300 nm in
length, which showed strong NIR absorption between 690 nm
and 790 nm and linear correlation between concentration and
PA signal intensity in vitro. Hence, to evaluate the effective PA
contrast obtainable in vivo, 200 µL of 1.2 µM RGD-conjugated
SWNTs have been injected into the tail vein of U87MG xeno-
graft tumor-bearing mice. PA 3D images acquired before and
4 h after the injection showed an 8-fold increase in the PA
Fig. 14 PA imaging of tumors in mice before and 1, 6, 12 and 24 h after
the intravenous injection of PEGylated Pd@Au nanoplates. Adapted from
ref. 209.
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signal compared to the system pre-injection. Successively, in
2010, they reported an improvement of their contrast thanks to
the conjugation of ICG to nanotubes. This has allowed a
strong increase in the PA contrast in vivo (300×) compared to
their previous work, but in this case the signal mainly orig-
inates from abundant ICG on the SWNT backbone. Finally, in
2012, the authors further extended their studies on the com-
parison between nanotubes conjugated to different NIR dyes
for in vivo PA experiments, which revealed that stronger NIR
absorber dyes allowed for brighter PA contrast.
Later, Chen et al. presented PEGylated single-walled carbon
nanohorns (SWNHs) with improved stability and biocompat-
ibility as a photothermal agent and for PA imaging both
in vitro and in vivo.217 Their SWNHs presented broad and
intense absorption in the NIR, well-suited for PA imaging and
PTT. After the assessment of their non-toxicity, the authors
injected 200 µL of 2 mg mL−1 PEGylated carbon nanohorns in
tumor-bearing mice and PA signal was monitored at the tumor
site before and up to 48 h after the injection. The PA signal
reached its maximum 24 h post-injection with a signal
enhancement factor of around 6, suggesting the involvement
of slow processes, such as EPR, in the accumulation of con-
trast in the tumor (Fig. 15). In addition, the proposed nano-
constructs showed remarkable results as PTT agents, thanks to
their high light-to-heat conversion efficiency, also exploited in
PA imaging.
Fullerenes appeared in the field of PA contrast agents when
Krishna et al. proposed it in 2010 using polyhydroxyfullerenes
(PHFs) for PA imaging of tumors.218 Water-soluble PHF and
chitosan-encapsulated PHF nanoparticles have shown good PA
contrast in vitro and negligible cytotoxicity, suggesting their
potential use in PTT and PA imaging in vivo. Hence, BT474
tumor cell-bearing mice have been intratumorally injected
with 30 µL of PHF 10 mg mL−1 or 0.45 mg mL−1 of PHF-func-
tionalized chitosan nanoparticles before undergoing PA
imaging analysis in the tumor region. Both injections showed
good contrast at the tumor site compared to control experi-
ments, generating signals as high as 4–5 times the endogenous
response.
Notwithstanding their promising contrast abilities, good
absorption coefficients and low reported toxicity, both carbon
nanotubes and PHFs display broad absorption throughout the
visible and the NIR: this can hamper the employment of multi-
spectral approaches for the discrimination of exogenous con-
trast from the endogenous one, generating wavelength-inde-
pendent contrast.
Graphitic carbon nanoparticles from natural sources were
prepared in 2013 by Wu et al. from honey in a domestic micro-
wave.219 The authors microwaved a dispersion of one macro-
molecular passivating agent (PEG or polysorbate) in honey
under an Ar atmosphere for 10–30 min, obtaining 7 nm lumi-
nescent carbon nanoparticles or carbon dots (OCNs). The par-
ticles showed broad absorption throughout the NIR; thus their
PA properties towards the identification of SLNs have been
tested. After the assessment of the in vitro potential of carbon
dots as PA contrast agents, 650 nm was chosen as the best exci-
tation wavelength to maximize the signal-to-noise ratio.
1–2 min after the intravenous injection of 100 µL of 25%vol
OCNs solution into living mice, PA images of the femoral
vessels have been acquired in vivo, showing a 60-fold PA signal
enhancement at the SLN right after the injection, which
rapidly decreased due to poor nanoparticle retention at the
lymph node.
Recently, Wu et al. deeply investigated PA contrast gener-
ated by porphyrin-containing carbon nanodots (C-Dots).220 In
particular, the authors conducted a partial hydrolysis of
5,10,15,20-tetrakis(4-aminophenyl)porphyrin (TAPP) and citric
acid to afford carbon dots with strong UV-visible and NIR
absorption. Reactive carboxylic moieties from citric acid were
observed to be directed towards the surface of the particles,
allowing for EDC-assisted amide coupling with α,ω-diamino
PEG. Hence, the carboxylic terminus of the C225 antibody has
been coupled to the C-Dots surface to exploit the high binding
affinity of the antibody for the epidermal growth factor recep-
tor (EGFR), allowing for active targeting. PA imaging analysis
in vitro revealed that deprotonation of the porphyrin induced
by alkaline pH completely inhibits the light absorption pro-
perties of the system, suggesting the possibility of obtaining
PA contrast triggered by the intrinsic acidity of cancer cells.
Fig. 15 In vivo PA images of tumor bearing mice intravenously injected
with PEGylated SWNHs. (a) PA signal from nanohorns before and 1 h,
4 h, 24 h and 48 h after the injection, showing clear accumulation in the
tumor. (b) The mean PA signal intensity at the tumor site over time.
Maximum accumulation was observed 24 h after the injection. (c) PA
images of hemoglobin (Hb) in the tumor at different time steps after the
administration. Adapted from ref. 217.
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As has been reviewed in detail, graphitic carbon nano-
structures offer good PA contrast and improved biocompatibil-
ity, despite displaying visible rather than NIR absorption and
very small size. Moreover, the molar absorption coefficient and
photothermal conversion efficiency of carbon nanoparticles
are rarely evaluated, making it hard to compare their perform-
ances with different nanostructures showing similar physical–
chemical features.
Finally, nanodiamonds have been studied by Zhang et al. for
their potential application as a PA contrast agent of tissues.221
Nanodiamonds (NDs) have been prepared by ion irradiation of
natural diamond powder at high dosage to create the vacancies
required for electronic transition, and thus absorption, to
occur. After in vitro and ex vivo PA imaging tests to assess the
pure contrast from nanodiamonds, in vivo experiments were
conducted. NDs have been subcutaneously injected into the
lower back of a mouse, revealing 919% signal enhancement at
the injection site and 567% contrast for a 3 mm deep injection.
However, despite the promising results about nanodiamonds’
cytotoxicity, the complexity of the synthesis procedure makes
NDs hardly employable in the clinics on a large scale.
Polymeric nanostructures
In two consecutive studies from 2014 and 2015, Pu et al. amply
described the performances of engineered semiconducting
polymer nanoparticles (SPNs) for preclinical PA imaging.222,223
In their first work, they reported a NIR-activatable PA probe for
the detection of the progression of pathological processes.
Poly(cyclopentadithiophene-alt-benzothiadiazole) had been
chosen to build SPNs by surfactant-assisted nanoprecipitation
because of its strong absorption in the NIR, suitable for PA
and fluorescence imaging. The nanoparticles displayed an
absorption peak at 660 nm, with a mass absorption coefficient
of 93 mL mg−1 cm−1. The PA performances of SPNs have been
evaluated in comparison with GNRs and SWNTs, both in vitro
and in vivo; 50 µg of nanoparticles were injected into mice for
lymph node tracking by PA and fluorescence detection. The
recorded amplitude of the PA signal increased by a factor of 10
after administration, allowing the clear visualization of several
lymph nodes in the region of injection, confirmed by fluo-
rescence imaging from the SPNs. The obtained PA amplitudes
for SPNs have been found to be 4 times greater than the ones
recorded for GNRs and SWNTs on a mass basis (Fig. 16).
Moreover, by nanoprecipitating a semiconducting polymer
with IR775S, a NIR dye sensitive to reactive oxygen species
(ROS), the authors built a smart PA nanoprobe whose PA spec-
trum was sensitive to endogenously generated ONOO- and
OCl- in vivo. Later, the same authors reported a new series of
diketopyrrolopyrrole-based SPNs for in vivo PA imaging of
tumor, as a proof-of-concept. The SPNs with the best perform-
Fig. 16 Comparison between the PA performances of SPNs, gold nanorods (GNRs) and SWNTs. (a) Normalized PA amplitude by mass or by mole.
(b) Nanoparticle signal stability with prolonged irradiation for the three systems. SPNs display constant PA emission, while GNRs are less stable due
to reshaping phenomena. (c) Calibration curves for PA contrast vs. concentration in vitro. (d) Recorded PA images at the site of injection of Matrigel-
included nanoparticles at 8 µg mL−1 concentration. Adapted from ref. 222.
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ances have been chosen out of 3 different polymers for PA
imaging in vivo, revealing strong contrast at the tumor site up
to 24 h post-injection. Remarkable results were obtained by
Huynh et al. in 2015 when they described the production of
convertible porphyrin microbubbles (pMBs) for multimodal
PA/US imaging.224 They first built micellar microbubbles
encapsulating perfluorocarbon gas using the porphyrin-con-
taining bacteriochlorophyll–lipid (BChl-lipid), generating a
microparticle displaying US contrast due to the high acoustic
impedance of gasses and PA and fluorescence imaging due to
absorption from porphyrin groups. Moreover, by exposure to
low-frequency US waves, the microbubbles were transformed
into smaller particles (5–500 nm) with the same optical pro-
perties as the former. After the stability of the PA contrast had
been assessed in vitro, tumor-bearing mice were injected with
150 µL of 8.4 × 107 pMBs solution to study and verify PA con-
trast and the micro-to-nano transformation by PA imaging.
More recently, Lyu reported a new theranostic nanoplatform
based on semiconducting polymers for PA imaging and
PTT.225 Molecularly-engineered poly[2,6-(4,4-bis(2-ethylhexyl)-
4H-cyclopenta-[2,1-b;3,4-b′]dithiophene)-alt-4,7-(2,1,3-benzothi-
adiazole)] (PCPDTBT) and (6,6)-phenyl-C71-butyric acid methyl
ester (PC70BM) nanoparticles have been prepared by nanopre-
cipitation. PCPDBTB is a semiconducting polymer with
absorption in the NIR (840 nm), while PC70BM is a highly
electrophilic and hydrophilic fullerene that enables intra-
molecular PET contrast. Thanks to HOMO–LUMO coupling
between the polymer and the fullerene units, increasing
amounts of fullerenes caused sensitive increment of PA signal
in the NIR. Hence, 200 µL of 100 µg mL−1 nanoparticle solu-
tion have been systemically injected into 4T1 tumor-bearing
mice, and PA images have been acquired 6 h post-injection.
Images revealed 1.8× PA signal enhancement for SPNs com-
pared to the injection of control nanoparticles. The nanocon-
struct also allowed for fluorescence imaging and PTT showing
promising results as a carbon-based biocompatible theranostic
platform.
The same year, Jiang described semiconducting polymer
nanoparticles with absorption in both the biological windows
in the NIR.226 SPNs were built by nanoprecipitation of a
mixture of poly[diketopyrrolopyrrole-alt-thiophene] and poly
(diketopyrrolopyrrole-alt-thiadiazoloquinoxaline) with PEG-b-
PPG-b-PEG as a stabilizer. The obtained SPNs displayed broad
NIR absorption at 744 nm and 1253 nm, allowing for NIR
dual-wavelength PA imaging for more accurate localization in
living tissues. As a proof-of-concept, in vivo PA imaging of the
rat brain vasculature was performed on a homemade PA
system equipped with two lasers, at 750 nm and 1064 nm. PA
signal remarkably increased at 750 nm after the intravenous
injection of 300 µL of 6 mg mL−1, but contrast at 1064 nm was
1.5 times stronger. These results demonstrate that SPNs can
serve as a PA contrast agent in the second biological window
of the electromagnetic spectrum, where high penetration
depth can be achieved.
To sum up, semiconducting conjugated polymers offer the
possibility to employ full-organic self-assembling materials for
generating efficient PA contrast in vivo in a wide spectral
range. However, thanks to the rigid conjugated structure of the
polymers, fluorescence phenomena widely occur upon NIR
laser excitation. Therefore, detailed studies on the photother-
mal conversion efficiencies should be conducted on different
SPNs to evaluate their effective PA contrast ability. Moreover,
detailed studies on the possible metabolic pathways involving
SPNs should be conducted to evaluate the possible toxicity of
cleaved monomers circulating in the body.
As a first application of protein-based PA contrast, Li et al.
developed a genetically encoded small NIR photochromic
protein capable of a strong PA effect, and a novel approach for
the application of PA imaging to the study of protein inter-
actions in vivo.227 In this work, the authors employed temporal
unmixing to discriminate PA signals from cells distributed at
different depths in biological systems. The different photo-
physical behavior of two different long-wavelength absorbing
bacterial phytochromes, RpBphP1 from Rhodopseudomonas
palustris and DrBphP-PCM from Deinococcus radiodurans, have
been exploited to develop a reversibly switchable PA computed
tomography system (RS-PACT) combined with single-impulse
panoramic PA imaging (SIP-PACT) and real-time detection of
genetically encoded NIR-absorbing protein probes. Briefly, U87
cells expressing the bacterial phytochrome DrBphP-PCM have
been injected in the right lobe of a living mouse liver, followed
by the injection of HEK-293 cells, engineered to express both
the bacterial phytochromes in the left lobe of the organ. By
exploiting the different decay profiles of the PA signal of the
two proteins over time, signals coming from the different
photoemitters have been efficiently separated. Furthermore,
DrBphP-PCM has been split into two of its main components,
named DrPAS and DrGAF-PHY, to achieve PA contrast only
when the two domains reconnected to form the photorespon-
sive core. By connecting the two distinct domains to different
interacting proteins and exploiting the photoswitching pro-
perties of the engineered system, the split phytochrome
DrSplit has been employed to efficiently study protein–protein
interactions (PPI) in vivo.
Hybrid nanocomposites
In this last section, we review complex hybrid nanosystems
composed of two or more different nanostructured sub-units,
capable of efficient PA contrast. These represent the most
advanced developments in the field, allowing for extremely
tunable responses and enhanced contrast due to the combi-
nation of the thermal expansions of the single components.
In 2009, Kim et al. reported the preparation of golden
carbon nanotubes (GNTs) as a biocompatible theranostic plat-
form for simultaneous PA-PT microscopy to overcome the
limitations in toxicity and absorption for carbon nano-
materials by taking advantage of the strong optical absorption
and consolidated biocompatibility of gold.228 The authors pre-
pared GNTs by depositing a 4–8 nm thick gold layer onto
SWNTS by slow reduction of HAuCl4 with no need for external
reductants. Similar to GNRs, GNTs showed longitudinal and
transverse LSPR absorption, at 520–530 nm and 850 nm,
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respectively, comparable with gold nanorods with an aspect
ratio of around 4–5. GNTs have been further conjugated with
an anti-LYVE-1 antibody for the evaluation of actively targeted
accumulation of contrast in vivo. Anti-LYVE-1 had been pre-
viously reported to specifically bind lymphatic endothelial
cells (LECs) lying on the internal surface of lymphatic vessels;
thus conjugation should have ensured contrast from lymphatic
vessels. After the introduction of the GNTs into the lymphatic
system of living mice, simultaneously acquired PA/PT micro-
scopic images revealed a 70-fold enhancement in the PA signal
at its maximum (1 h post-injection), allowing for noiseless
visualization of lymphatics in the mesentery.
In addition, Liu et al. have in 2013 described the implemen-
tation of Au–Cu2−xSe heterodimer nanoparticles as a plasmo-
nic–semiconducting hybrid contrast agent for in vivo PA
imaging.229 Nanoparticles have been obtained using gold
nanoparticles as seeds for the seeded growth of Cu2−xSe nano-
crystals. The interaction between plasmonic and semiconduct-
ing domains generates broad absorption across both the
visible and the NIR, up to 1750 nm. The change in PA signal
was monitored in the axillary vasculature rats (at 1064 nm)
after successive intravenous injection of 200 µL of 4 mg mL−1
Au–Cu2−xSe nanocrystals, showing 200% contrast enhance-
ment 1 h after the first injection and 290% 1 h after the
second injection.
Later, Wang et al. employed PA imaging for the detection of
gastric cancer using RGD-conjugated SiO2-coated gold nano-
rods (sGNRs) on the surface of multiwalled carbon nanotubes
(MWNTs).230 The two nanostructures have been coupled via
amide bond formation between amino groups on sGNRs and
the carboxylic residues on MWNTs. The absorption spectrum
of MWNTs/sGNRs displayed broad absorption in the NIR, with
the LSPR peak from GNRs still present at 680 nm. Contrast
efficiency was tested in vivo by PA imaging of a subcutaneous
gastric cancer xenograft model in mice, showing contrast
enhancement and accumulation at the tumor site up to 12 h
post-injection. Moreover, 20% PA signal enhancement has
been confirmed to be a consequence of sGNR interaction with
MWNTs at the quantum level in the hybrid nanostructure.
The same type of interaction at the nanoscale was also
explored later on when Moon et al. described their experi-
ments with reduced graphene oxide coated gold nanorods
(r-GO-GNRs) for PA imaging.231 In their work, the authors
studied the enhanced NIR absorption properties (λmax ≈
750 nm) of r-GO-GNRs and confirmed their excellent photo-
thermal stability and photoacoustic efficiency. Furthermore, to
prove the promising PA contrast in vivo, 50 µL of 1.25 nM
r-GO-GNRs have been dispersed in Matrigel and injected into
the back of mice. PA imaging at the injection site (at 750 nm)
revealed a 40-fold signal enhancement from the composite
nanostructure (Fig. 17).
Then, Gao in 2016 reported the PA performances of a
different Au-graphene hybrid as an activatable theranostic
agent.232 Their nanoconstruct was based on the GO-Au nano-
particle nanocomposite that was covalently connected to the
matrix metalloprotease-14 (MMP-14) labeled with a NIR dye.
PA imaging revealed a significant contrast in vivo compared to
AuNPs and GO alone, as reported previously. The PA enhance-
ment due to the coupling between gold and carbon is believed
to be due to fluorescence quenching from gold towards GO,
which causes an increase in the photoacoustic efficiency of the
graphene sheets. More recently, Chen et al. described the
Fig. 17 In vivo PA imaging experiments on GNRs, GO-GNRs and r-GO-GNRs. (A) PA images of the injection sites obtained by changing the laser
power from 4 to 9 mJ cm−2. (B) Linear relationship between PA amplitude and laser power; r-GO-GNRs display stronger PA amplitude and higher
sensitivity towards variations in laser power. Adapted from ref. 231.
Review Biomaterials Science













































































preparation of composite nanomodulators for dynamic con-
trast-enhanced PA imaging.233 The authors prepared poly(n-
isopropylacrylamide) (PNIPAM) nanogels loaded with GNRs
and CuS QDs. The two nanosystems have been compared on
several aspects, such as optical cross-section, absorption tun-
ability, size and photostability. Dynamic contrast-enhanced
imaging allows separating static background signals from
dynamic signals from the contrast, hence increasing the
signal-to-noise ratio and allowing for unambiguous identifi-
cation of the contrast.
In 2018, we reported the production of a triple-modality
imaging probe based on MnFe2O4 nanoparticles, GNRs and
fluorescein, allowing for unambiguous contrast detection
in vivo.234 Silica-coated magnetic nanoparticles have been func-
tionalized with amino- and azido-modified silanes, further
coupled via click chemistry to alkyne-functionalized GNRs, to
achieve a smart assembly capable of triple fluorescence, MRI
and PA imaging contrast in vivo. We evaluated PA signals by
injection of a few microliters of a nanoprobe solution in
chicken breast tissue, revealing good contrast and high signal-
to-noise ratio even at concentrations as low as 34 µM, which cor-
responded to a 50-fold PA signal enhancement compared to the
background. Moreover, the PA signal coming from the thermo-
elastic expansion of GNRs was observed to be constant with
time, revealing no reshaping involving the gold nanostructure.
The outstanding properties of these latest examples demon-
strate the possibility to covalently combine the PA features of
different nanostructures to nanomaterials that display very
different properties, allowing for the fabrication of advanced
nanocomposites with unique diagnostic efficacies. However,
the interactions of the combined nanosystems in a biological
environment should be evaluated in each case, and the stabi-
lity of the connections between independent blocks must be
ensured to avoid leakage of some of the components of the
hybrid nanocomposites.
Conclusions
In conclusion, nanostructured contrast agents have been
reported to be capable of making PA imaging an efficient tool
for the noninvasive visualization of superficial and deep
tissues. The appropriate contrast agent should be chosen for
each application according to its optical properties, biocom-
patibility and photostability, and it can be engineered in a
large variety of ways to couple PA imaging to other imaging
modalities. Contrast agents for PA imaging can often serve as
PTT agents, thus representing good candidates as theranostic
platforms against cancer. However, more concern should be
directed towards detailed and representative biocompatibility
studies not only for each class of contrast agents, but for each
single nanosystem. Parameters such as particle size, shape,
surface charge, coating and roughness are key parameters for
determining the toxicity mechanism of nanomaterials and
their path in complex biosystems. For example, preliminary
pharmacokinetics studies reveal that spherical gold nano-
particles can cause cell division dysfunctions while cylindrical
gold nanorods are related to chronic inflammation.235
Nowadays, the main limitations concerning contrast media for
PA imaging are related to the long-term toxicity and biodistri-
bution of the nanostructures after administration and their
stability upon prolonged irradiation.
Thus, detailed studies are yet to be conducted, but prelimi-
nary studies confirm the promising features of several nano-
structures for in vivo applications. Moreover, contrast-based PA
imaging could be employed in the near future for clinical
trials on humans, highlighting the need for contrast agents to
achieve deeper tissue penetration and higher photostability.
In perspective, by analysing the market trend in developing
novel contrast agents, which is continuously growing, and in
consideration of the fact that PA is an easy, portable, low cost
imaging technique that can be coupled with commonly and
largely distributed echographic instrumentation, a future
increase of PA applications can be expected together with an
improvement in contrast agent development, specificity and
applicability.
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